(714) 771-1213 Contact Us
REQUEST INFO/CONSULTATION
First Name
Last Name
Email
Phone Number
How did you hear about us?
Comments

Get Social
Review Us Online

Current Studies

Glaucoma is a common eye condition in which the fluid pressure inside the eye rises to a level higher than healthy for that eye. If untreated, it may damage the optic nerve, causing the loss of vision or even blindness. The treatment of glaucoma may include medication, surgery, or laser surgery. Eyedrops or pills alone can usually control glaucoma, although they cannot cure it.

1. Hydrus-4
Hydrus™ Is a Microstent, developed by Ivantis, for the treatment of patients with primary open angle glaucoma (POAG). The Hydrus procedure is designed to be less invasive than traditional glaucoma surgery and can be performed during cataract surgery using the same microsurgical incisions. The enrollment for this study is closed.

2. Compass-XT 
CyPass® is a Microstent, developed by Alcon, for the treatment of patients with mild to moderate primary open-angle glaucoma (POAG) and cataracts.  The CyPass implantation procedure is designed to be less invasive than traditional glaucoma surgery and can be performed during cataract surgery using the same microsurgical incisions. After we concluded a two-year trial with successful results, we are now extending the observation period to five years.  The enrollment for this study is closed.


Chances are high if you are in your 40s or beyond you have started to notice the effects of presbyopia. The loss of near vision and the ability to perform tasks that require near vision is part of the normal aging process. In the eye, the crystalline lens is located just behind the iris and the pupil. Tiny ciliary muscles pull and push the lens, adjusting its curvature, and thereby adjusting the eye’s focal power to bring objects into focus. As individuals age, the lens becomes less flexible and elastic, and the muscles become less powerful. Because these changes result in inadequate adjustment of the lens of the eye for various distances, objects that are close will appear blurry. The major cause of presbyopia is loss of elasticity of the lens of the eye. Loss of ciliary muscle power, however, is also believed to contribute to the problem.

3. Raindrop
The Raindrop® Near Vision Inlay by Revision Optics is a microscopic transparent hydrogel inlay that is designed to correct presbyopia. Raindrop® is the first and only corneal inlay that creates a prolate-shaped cornea, and is easily placed under a femtosecond laser flap. This study is being conducted in patients who underwent cataract surgery in the past and want improvement of near vision.  The enrollment for this study is open and we are currently screening patients to participate in this study.

4. VisAbility
Another alternative to correct presbyopia is the VisAbility micro-insert system by Refocus Group.  The procedure is a minimally invasive outpatient procedure, which typically takes 20 to 30 minutes per eye. Four small plastic implant segments (about the size of a grain of rice) are surgically placed into the white of your eyes. The segments are small, normally hidden by the eyelids and are generally not noticeable after placement. It is anticipated that these implant segments will create additional space inside the eye to restore the natural tension of the muscle tissue inside the eye.  The enrollment for this study is closed.


Astigmatism is a condition where the cornea (front surface) of the eye, is not curved uniformly, it is shaped more like a football than spherical like a baseball. With astigmatism, the light rays passing through the cornea do not focus on a single point of the retina. This may cause objects both near and far away to appear blurry, shaded or elongated. An intraocular lens designed to reduce astigmatism is called a “toric” IOL. Cataract patients who have astigmatism, and who do not want to wear glasses to see clearly at distance can choose Toric intraocular lenses to be implanted during surgery.
We are conducting two different studies related with Toric intraocular lenses.

5. Post-Approval Study of the Tecnis Toric IOL Models ZCT300 and ZCT400
This study sponsored by Abbott evaluates the rates of visual distortion in patients with cataract implanted with the TECNIS Toric IOLs (ZCT300 and ZCT400) The TECNIS Toric IOLs are marketed in the US, Europe and other countries worldwide.

6. Clinical Performance of the Cassini TCA for Toric IOLs
This study enrolls patients that will have cataract surgery with Toric intraocular lenses, used to correct astigmatism, and compares actual and simulated Toric IOL calculations with different keratometric measurement devices, including the Cassini topographer.

7. Quality of Vision of Patients Implanted with Intraocular Lens (IOL) After Cataract Surgery
In some cases, healthy patients with successful cataract surgeries report visual disturbances despite a normal observation from the physician's perspective. To further our understanding of these phenomena, ClarVista is sponsoring a patient reported outcome study on healthy, post-surgical cataract patients that do not have any other ocular conditions. The primary goal for this study is to understand how different intraocular lenses interact with different patients. Through an in-depth questionnaire that asks about visual issues, we can evaluate which visual problems are common among different IOLs. The results from this study will give us a better understanding of intraocular lens compatibility and allow us to refine our lens recommendations. The enrollment for this study is open and we are currently screening patients to participate in this study.  


For more information about our clinical studies and to see if you qualify please contact:

Ashley Owyang, OD
Clinical Study Coordinator
P (714)-771-1213
F (714)-771-7126